Cargando…
Anaplastic lymphoma kinase inhibitors and their effect on the kidney
Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non–small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treat...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308093/ https://www.ncbi.nlm.nih.gov/pubmed/35892021 http://dx.doi.org/10.1093/ckj/sfac062 |
_version_ | 1784752913206214656 |
---|---|
author | Bonilla, Marco Jhaveri, Kenar D Izzedine, Hassan |
author_facet | Bonilla, Marco Jhaveri, Kenar D Izzedine, Hassan |
author_sort | Bonilla, Marco |
collection | PubMed |
description | Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non–small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice. |
format | Online Article Text |
id | pubmed-9308093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93080932022-07-25 Anaplastic lymphoma kinase inhibitors and their effect on the kidney Bonilla, Marco Jhaveri, Kenar D Izzedine, Hassan Clin Kidney J CKJ Review Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non–small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice. Oxford University Press 2022-02-26 /pmc/articles/PMC9308093/ /pubmed/35892021 http://dx.doi.org/10.1093/ckj/sfac062 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | CKJ Review Bonilla, Marco Jhaveri, Kenar D Izzedine, Hassan Anaplastic lymphoma kinase inhibitors and their effect on the kidney |
title | Anaplastic lymphoma kinase inhibitors and their effect on the kidney |
title_full | Anaplastic lymphoma kinase inhibitors and their effect on the kidney |
title_fullStr | Anaplastic lymphoma kinase inhibitors and their effect on the kidney |
title_full_unstemmed | Anaplastic lymphoma kinase inhibitors and their effect on the kidney |
title_short | Anaplastic lymphoma kinase inhibitors and their effect on the kidney |
title_sort | anaplastic lymphoma kinase inhibitors and their effect on the kidney |
topic | CKJ Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308093/ https://www.ncbi.nlm.nih.gov/pubmed/35892021 http://dx.doi.org/10.1093/ckj/sfac062 |
work_keys_str_mv | AT bonillamarco anaplasticlymphomakinaseinhibitorsandtheireffectonthekidney AT jhaverikenard anaplasticlymphomakinaseinhibitorsandtheireffectonthekidney AT izzedinehassan anaplasticlymphomakinaseinhibitorsandtheireffectonthekidney |